Hospital
Spectrum Health Kelsey
Spectrum Health Kelsey was paid $4.49M by Medicaid between Jan 2018 and Sep 2023, across 104 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoSPECTRUM HEALTH KELSEY
LAKEVIEW, MI 48850
LAKEVIEW, MI 48850
33aNPI1538102173assigned 06/13/2006
33bProvider typeCritical Access Hospital
28Total paid$4.49M
24GClaims100,480
24DCodes billed104
24AFirst – last monthJan 2018 – Sep 2023
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#18 of 31
Median peer was paid$6.03M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,701 | $588K | |
| 2019 | 13,501 | $453K | |
| 2020 | 14,668 | $695K | |
| 2021 | 21,454 | $1.02M | |
| 2022 | 20,501 | $1.01M | |
| 2023 | 13,655 | $722K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 7,756 | 7,384 | $1.17M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 4,873 | 4,660 | $1.13M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 1,949 | 1,853 | $618K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 8.2% | 3,084 | 2,845 | $367K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.5% | 2,640 | 2,575 | $247K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.4% | 6,560 | 1,746 | $199K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 885 | 870 | $172K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 1,232 | 1,189 | $89K |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 1,555 | 1,516 | $72K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 1,959 | 1,815 | $57K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.3% | 1,533 | 1,505 | $57K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 2,268 | 2,060 | $55K |
92 more codes
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,322 | $31K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 428 | $24K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,095 | $22K |
| 80053 | Comprehensive metabolic panel | <1% | 6,403 | $17K |
| 80061 | Lipid panel | <1% | 1,680 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,564 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,100 | $11K |
| 71045 | Radiologic examination, chest; single view | <1% | 188 | $10K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 490 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 559 | $9K |
| 80050 | General health panel | <1% | 289 | $8K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,205 | $8K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 80 | $7K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 212 | $7K |
| 97162 | <1% | 116 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,041 | $6K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 388 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 301 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 108 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,929 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 26 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 59 | $3K |
| 85027 | <1% | 909 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 762 | $2K |
| 83735 | <1% | 869 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 24 | $2K |
| 85610 | <1% | 1,028 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 19 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 18 | $1K |
| 73630 | <1% | 179 | $1K | |
| 81001 | <1% | 4,260 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 64 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 67 | $1K |
| 82728 | <1% | 150 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $1K |
| 72100 | <1% | 25 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $922.62 |
| 73610 | <1% | 68 | $801.67 | |
| 82947 | <1% | 235 | $729.25 | |
| 82607 | <1% | 68 | $610.56 | |
| 73030 | <1% | 27 | $523.40 | |
| 83550 | <1% | 88 | $465.04 | |
| 83540 | <1% | 115 | $446.76 | |
| 81025 | <1% | 1,658 | $432.70 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,548 | $416.80 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 43 | $400.82 |
| 73562 | <1% | 13 | $392.38 | |
| 84439 | <1% | 69 | $371.78 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 25 | $348.12 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 409 | $318.09 |
| 83690 | <1% | 1,474 | $296.77 | |
| 82565 | <1% | 338 | $277.78 | |
| 73130 | <1% | 29 | $261.87 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 347 | $162.60 |
| 84702 | <1% | 19 | $147.55 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 455 | $126.61 |
| 86140 | <1% | 27 | $83.63 | |
| 82570 | <1% | 26 | $77.84 | |
| 83880 | <1% | 26 | $63.14 | |
| 84484 | <1% | 960 | $35.64 | |
| 87503 | <1% | 18 | $29.74 | |
| 87070 | <1% | 47 | $21.68 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,723 | $20.97 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,190 | $20.58 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,759 | $20.36 |
| 87077 | <1% | 24 | $18.27 | |
| 87081 | <1% | 451 | $13.91 | |
| 87807 | <1% | 68 | $10.48 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,444 | $9.06 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 697 | $8.41 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 12 | $8.39 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,390 | $4.39 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 515 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,354 | $0.00 |
| 90715 | 0% | 27 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 26 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 13 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 14 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 202 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 73 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 68 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 196 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 125 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 122 | $0.00 |
| 83605 | 0% | 197 | $0.00 | |
| 87040 | 0% | 13 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 171 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 40 | $0.00 |
| 85379 | 0% | 14 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 30 | $0.00 |
| 96376 | 0% | 103 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, RYAN (VP FINANCE CFO)
| Provider | Location | Paid |
|---|---|---|
| Wisdom Teeth Guys - Texas, PLLC | Arlington, TX | $3.76M |
| Spectrum Health United | Greenville, MI | $1.03M |
| Spectrum Health United | Greenville, MI | $687K |
| Spectrum Health United | Lakeview, MI | $139K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.